The UK's National Institute for Health and Care Excellence (NICE) has recommended that Astrazeneca's heart failure med Forixga (dapagliflozin) should have its indication expanded to adults regardless of the degree of their left ventricular ejection fraction (LVEF). The drug was previously indicated with patients with reduced LVEF of 40% or lower.
According to Emily Kimber, “NICE's final draft guidance was supported by results from AZ's phase 3 DELIVER trial, which evaluated Forixga in HF patients with LVEF greater than 40%, with or without type 2 diabetes. The study met its primary endpoint, with Forxiga reducing the composite outcome of cardiovascular death or worsening HF by 18%.”
To read more, click here.
(Source: PM Live, May 19th, 2023)